Introgen Therapeutics, Inc. (Nasdaq: INGN) gained a worldwide exclusive license to a family of patent applications directed to combination therapy using ADVEXIN® with inhibitors of epidermal growth factor receptors (EGFr inhibitors), such as Erbitux™, Vectibix™, Tarceva™ and Iressa™.
The said family of patents was licensed to Introgen from The University of Texas System M. D. Anderson Cancer Center: based on the discovery by scientists (at M.D. Anderson Cancer Center) that p53 and mda7 therapies can work synergistically with inhibitors of epidermal growth factor receptors to arrest tumor growth.
According to Robert E. Sobol, M.D., Introgen's senior vice president of Medical and Scientific Affairs:
Find more details from the press release.
"Introgen is very encouraged by the results of preclinical studies combining these two agents. Combining ADVEXIN with EGFr inhibitors such as Erbitux, Vectibix or other such drugs represent a logical extension of our knowledge of cancer biology leading to improved cancer therapies.
These agents are targeted to fundamental molecular defects that can inhibit tumors. Our clinical studies have shown enhanced clinical activity when ADVEXIN is administered in combination with traditional treatments like surgery, chemotherapy, or radiation therapy.
We look forward to expanding our programs to include this new exciting approach of combining biological therapies."
Comment Preview